Geron Appoints New CEO, Sees 182.41% Upside with Average Price Target of $3.39

Geron Corporation has appointed Harout Semerjian as its new President and CEO, effective August 7, 2025. Semerjian has a proven track record of success from his tenure at GlycoMimetics. Wall Street analysts predict a potential upside of 182.41% with an average price target of $3.39. The consensus recommendation for Geron remains strong at an "Outperform" status from brokerage firms.

FOSTER CITY, Calif. — Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on developing treatments for blood cancer through telomerase inhibition, has appointed Harout Semerjian as its new President and Chief Executive Officer (CEO). Semerjian will take over the role effective August 7, 2025, succeeding Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Bir will continue to serve on Geron’s Board of Directors.

Semerjian brings over 30 years of commercial experience in hematology and oncology, having previously held leadership positions at Novartis, Ipsen, Immunomedics, and most recently, GlycoMimetics. His appointment comes as Geron works to expand awareness and access to RYTELO, its first-in-class telomerase inhibitor approved in the United States and European Union for treating certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.

Geron's revenue growth prospects look promising, with analysts forecasting significant sales growth for the current year. However, the company has been experiencing rapid cash burn and has a strong liquidity position, with more cash than debt on its balance sheet. The company reported its first-quarter 2025 earnings, meeting analysts’ expectations with an earnings per share (EPS) of -0.03, but revenue fell short of projections, coming in at $39.6 million against the anticipated $50.46 million. Goldman Sachs resumed coverage of Geron with a Sell rating, setting a $1.00 price target, due to disappointing sales of its commercial drug, Rytelo.

Semerjian holds a B.S. in Biology from Lebanon American University and an MBA from Cornell University and Queen’s University, Canada. He is well-suited to lead Geron into its next chapter of growth, according to Elizabeth O’Farrell, Chairman of Geron’s Board of Directors.

Wall Street analysts predict a potential upside of 182.41% with an average price target of $3.39, and the consensus recommendation for Geron remains strong at an "Outperform" status from brokerage firms.

References:
[1] https://www.investing.com/news/company-news/geron-appoints-harout-semerjian-as-new-ceo-amid-rytelo-expansion-93CH-4172787
[2] https://www.businesswire.com/news/home/20250507966966/en/Geron-Corporation-Reports-First-Quarter-2025-Financial-Results-and-Recent-Business-Highlights